Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present one oral late breaking communication and two poster presentations featuring blarcamesine at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, being held in San Diego, California from December 1-4, 2025.

Read more at globenewswire.com